What do systematic reviews say?

Summary of findings table ‐ Aspiration/flush vs aspiration

• Follicular flushing during oocyte retrieval in assisted reproductive techniques 2022 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 785 participants
  Low

Summary of findings table ‐ Aspiration/flush vs aspiration

• Follicular flushing during oocyte retrieval in assisted reproductive techniques 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 160 participants
  Low

Summary of findings table ‐ Aspiration/flush vs aspiration

Summary of findings table ‐ Aspiration/flush showed no clear difference in clinical pregnancy rate per woman randomised compared with aspiration (low certainty).

• Follicular flushing during oocyte retrieval in assisted reproductive techniques 2022 · Cochrane Headline outcomes only
  OR 1.13 [0.85, 1.51]
  7 studies · 939 participants
  Low

Summary of findings table ‐ Aspiration/flush vs aspiration

• Follicular flushing during oocyte retrieval in assisted reproductive techniques 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 3 participants
  Low

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes live birth rate per couple compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.37 [0.69, 2.71]
  2 studies · 366 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes miscarriage rate per couple compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.09 [0.63, 1.87]
  6 studies · 821 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes incidence of ectopic pregnancies per couple compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 2.28 [0.33, 15.62]
  3 studies · 320 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes incidence of OHSS per couple (mild–severe) compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.07 [0.6, 1.9]
  3 studies · 370 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes incidence of multiple pregnancies per couple compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 0.86 [0.33, 2.2]
  4 studies · 504 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes ongoing pregnancy rate per couple compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.19 [0.8, 1.76]
  3 studies · 476 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

Glucocorticoids showed no clear difference in clinical pregnancy rate per couple –pregnancy rate per couple… compared with no glucocorticoids or placebo (low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.17 [0.95, 1.44]
  13 studies · 1967 participants
  Low
• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.2 [0.87, 1.67]
  6 studies · 780 participants
  Very low
• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.15 [0.87, 1.5]
  7 studies · 1187 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes clinical pregnancy rate per couple – subgroup IVF compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.44 [1, 2.08]
  5 studies · 724 participants
  Very low

Any glucocorticoid vs no glucocorticoids or placebo

It is very uncertain whether glucocorticoids changes clinical pregnancy rate per couple – subgroup ICSI compared with no glucocorticoids or placebo (very low certainty).

• Peri‐implantation glucocorticoid administration for assisted reproductive technology cycles 2022 · Cochrane Headline outcomes only
  OR 1.08 [0.81, 1.42]
  6 studies · 992 participants
  Very low

Antioxidants vs placebo or no treatment

It is very uncertain whether antioxidants changes live birth rate per couple randomised compared with placebo or no treatment (very low certainty).

• Antioxidants for male subfertility 2022 · Cochrane Headline outcomes only
  OR 1.43 [1.07, 1.91]
  12 studies · 1283 participants
  Very low

Antioxidants vs placebo or no treatment

Antioxidants may leads to higher clinical pregnancy rate per couple randomised compared with placebo or no treatment (low certainty).

• Antioxidants for male subfertility 2022 · Cochrane Headline outcomes only
  OR 1.89 [1.45, 2.47]
  20 studies · 1706 participants
  Low

Antioxidants vs placebo or no treatment

It is very uncertain whether antioxidants changes adverse events ‐ Miscarriage compared with placebo or no treatment (very low certainty).

• Antioxidants for male subfertility 2022 · Cochrane Headline outcomes only
  OR 1.46 [0.75, 2.83]
  6 studies · 664 participants
  Very low

Antioxidants vs placebo or no treatment

Antioxidants may leads to higher adverse events ‐ Gastrointestinal compared with placebo or no treatment (low certainty).

• Antioxidants for male subfertility 2022 · Cochrane Headline outcomes only
  OR 2.7 [1.46, 4.99]
  16 studies · 1355 participants
  Low

Conjugated oral oestrogens vs transdermal 17ß‐estradiol

• Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 12 participants
  Very low

Low vs high 17ß‐oestradiol dose

The review found no eligible studies for this question.

• Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low vs high 17ß‐oestradiol dose

The review found no eligible studies for this question.

• Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found